Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGN NASDAQ:BBNX NYSE:BVS NYSE:ELMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$15.52+1.0%$12.03$9.22▼$21.00$714.77M1794,895 shs390,960 shsBBNXBeta Bionics$14.80-6.8%$15.31$8.89▼$24.50$643.36MN/A523,091 shs303,265 shsBVSBioventus$7.29-0.4%$6.76$5.81▼$14.38$600.25M0.83396,917 shs147,965 shsELMDElectromed$19.52+1.9%$19.66$13.74▼$35.56$163.65M0.3882,333 shs24,729 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen-0.84%+8.47%+36.17%+34.74%+25.29%BBNXBeta Bionics-8.00%+11.67%+16.85%+2.06%+1,587,999,900.00%BVSBioventus+1.95%+0.14%+16.93%+12.62%-8.50%ELMDElectromed-2.69%-0.93%+5.10%-8.19%+28.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen3.0667 of 5 stars3.52.00.00.03.72.50.6BBNXBeta Bionics2.8092 of 5 stars4.40.00.00.03.20.80.0BVSBioventus3.0699 of 5 stars3.40.00.00.02.03.31.3ELMDElectromed1.2268 of 5 stars2.03.00.00.00.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$26.0067.53% UpsideBBNXBeta Bionics 2.75Moderate Buy$22.5652.40% UpsideBVSBioventus 2.75Moderate Buy$13.7588.51% UpsideELMDElectromed 4.00Strong Buy$33.5071.66% UpsideCurrent Analyst Ratings BreakdownLatest ELMD, BBNX, AXGN, and BVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.007/30/2025BBNXBeta BionicsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$15.00 ➝ $17.007/22/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$29.007/21/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$12.006/16/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.006/12/2025BBNXBeta BionicsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$30.005/30/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$16.005/30/2025BBNXBeta BionicsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.00(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$187.34M3.81N/AN/A$2.44 per share6.36BBNXBeta Bionics$78.02M8.25N/AN/A$6.94 per share2.13BVSBioventus$564.14M1.07$0.58 per share12.58$2.80 per share2.61ELMDElectromed$61.44M2.66$0.47 per share41.36$5.10 per share3.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$9.96M-$0.10N/AN/AN/A-2.29%-4.43%-2.34%11/6/2025 (Estimated)BBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/ABVSBioventus-$156.23MN/AN/A15.86N/A-7.11%15.61%4.01%N/AELMDElectromed$5.15M$0.7926.02∞N/A11.34%15.71%13.37%N/ALatest ELMD, BBNX, AXGN, and BVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025BBNXBeta Bionics-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ABBNXBeta BionicsN/AN/AN/AN/AN/ABVSBioventusN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.594.142.67BBNXBeta BionicsN/A14.6813.79BVSBioventus1.851.410.99ELMDElectromedN/A5.104.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%BBNXBeta BionicsN/ABVSBioventus62.94%ELMDElectromed40.82%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%BBNXBeta BionicsN/ABVSBioventus33.00%ELMDElectromed14.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45046.01 million44.73 millionOptionableBBNXBeta Bionics29443.47 millionN/AN/ABVSBioventus1,20082.68 million54.46 millionNot OptionableELMDElectromed1608.39 million7.36 millionOptionableELMD, BBNX, AXGN, and BVS HeadlinesRecent News About These CompaniesElectromed, Inc. to Report Q4 Fiscal 2025 Financial Results on August 26, 2025August 12, 2025 | businesswire.comUniversal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Electromed, Inc. (NYSE:ELMD)August 5, 2025 | marketbeat.comElectromed, Inc. to Participate in the Canaccord Genuity 45th Annual Growth ConferenceJuly 29, 2025 | bakersfield.comBElectromed Joins Key Indexes Backed By Solid Growth And StabilityJuly 27, 2025 | msn.comElectromed stock is a buy, this analyst saysJuly 24, 2025 | cantechletter.comCRoth Capital Forecasts Electromed FY2025 EarningsJuly 24, 2025 | marketbeat.comRoth Capital Initiates Coverage of Electromed (ELMD) with Buy RecommendationJuly 23, 2025 | msn.comElectromed (NYSE:ELMD) Raised to "Strong-Buy" at Roth CapitalJuly 23, 2025 | marketbeat.comElectromed (NYSE:ELMD) Coverage Initiated at Roth CapitalJuly 22, 2025 | marketbeat.comFreedom Broker initiates coverage on Electromed stock with Buy ratingJuly 3, 2025 | investing.comElectromed, Inc. to Present at the Investor Summit Virtual on June 10, 2025June 9, 2025 | gurufocus.comElectromed, Inc. to Present at the Investor Summit Virtual on June 10, 2025 | ELMD Stock NewsJune 9, 2025 | gurufocus.comElectromed, Inc. to Present at the Investor Summit Virtual on June 10, 2025June 9, 2025 | accessnewswire.comAElectromed, Inc. to Join Russell 2000® and Russell 3000® IndexesMay 27, 2025 | businesswire.comHere is Why Growth Investors Should Buy Electromed (ELMD) NowMay 20, 2025 | zacks.comElectromed signals ongoing sales force expansion and highlights $5M share repurchase amid double-digit revenue growthMay 13, 2025 | msn.comElectromed, Inc. (ELMD) Q3 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comElectromed, Inc. Announces Fiscal 2025 Third Quarter ResultsMay 13, 2025 | businesswire.comElectromed, Inc. to Present at the LD Micro Invitational XVApril 3, 2025 | newsfilecorp.comNElectromed Announces Share Repurchase Authorization - Quick FactsMarch 12, 2025 | nasdaq.comElectromed announces $5M share repurchase authorizationMarch 10, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELMD, BBNX, AXGN, and BVS Company DescriptionsAxoGen NASDAQ:AXGN$15.52 +0.16 (+1.04%) As of 02:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Beta Bionics NASDAQ:BBNX$14.80 -1.08 (-6.80%) As of 02:38 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Bioventus NYSE:BVS$7.29 -0.03 (-0.36%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Electromed NYSE:ELMD$19.52 +0.36 (+1.85%) As of 02:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer's Flight Milestones & Defense Wins Excite Wall Street Home Depot Holds Gains After Narrow Q2 Misses 2 Powerful Forces Now Back Intel's Turnaround The Case for Buying NVIDIA Stock Ahead of the Robotics Surge Medtronic: The Opportunity Gets Healthier for Income Investors Palo Alto Networks Uptrend Confirmed! New Highs Set by Year’s End Micron Stock Still Cheap Despite 25% Rally, Analysts Say Qualcomm Just Passed 1 Major Test, But Can It Pass the Next? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access